TERN-101

TERN-101 is a potent, non-bile acid, liver-selective small molecule agonist of the farnesoid X receptor (FXR), a nuclear receptor highly expressed in the liver and small intestine. FXR plays a key role in regulating bile acid synthesis, lipid metabolism, inflammation, and fibrosis. By activating FXR, TERN-101 modulates these pathways to potentially treat non-alcoholic steatohepatitis (NASH). The drug has demonstrated significant suppression of 7α-hydroxy-4-cholesten-3-one (7α-C4), an established biomarker for hepatic FXR activation. It is being developed by Terns Pharmaceuticals under license from Eli Lilly and Company[2][3][5][6][7]. Clinical studies have shown that TERN-101 is well-tolerated with evidence of target engagement and improvement in biomarkers associated with NASH[5][8].

Other names

6-(4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic acid